Historical evolution of thoracoscopic repair for congenital diaphragmatic hernia: an era-based systematic review and meta-analysis.

Surg EndoscSep 9, 2026 (epub)
Clinical ResearchCardiothoracic SurgeryOpen access

Masaya Yamoto, Miharu Ito, Kouji Nagata et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the outcomes of thoracoscopic repair for congenital diaphragmatic hernia (CDH) over time, analyzing 27 studies with 9,396 patients. The overall recurrence rate after thoracoscopic repair was significantly higher than open repair (RR 2.43, 95% CI 1.88-3.14, p < 0.001), but post-2015 studies showed improved comparability (RR 1.43, 95% CI 0.81-2.54).

Key findings

  • Overall recurrence after thoracoscopic repair was significantly higher than open repair (RR 2.43, 95% CI 1.88-3.14, p < 0.001).
  • Post-2015 studies showed improved recurrence rates, with RR 1.43 (95% CI 0.81-2.54).
  • Meta-regression indicated a significant temporal reduction in recurrence disadvantage (p = 0.0059).
  • Mortality was lower in the thoracoscopic group, likely due to selection bias.

Why it matters

Understanding the evolving outcomes of thoracoscopic repair for CDH is crucial for clinicians, as it informs surgical decision-making and patient selection, particularly in light of improving techniques and outcomes over time.

Source

PubMed · PMID 42717045Free full text on PubMed Central

Published in Surg Endosc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiothoracic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.